Passive but not active CD8+ T cell-based immunotherapy interferes with liver tumor progression in a transgenic mouse model

Journal of Immunology

Volumn 161, Issue 10, 1998, Pages 5133-5137

  Romieu, Raphaëlle ^a,c   Baratin, Myriam ^a   Kayibanda, Michèle ^a   Lacabanne, Valérie ^a   Ziol, Marianne ^b   Guillet, Jean Gérard ^a   Viguier, Mireille ^a  

^a INSERM   (France)

^b HÔPITAL JEAN VERDIER   (France)

^c INSTITUT COCHIN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN RECOGNITION; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; IMMUNOGENICITY; LIVER TUMOR; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TRANSGENIC MOUSE;

EID: 0032533459     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Van den Eynde, B., and P. van der Bruggen. 1997. T cell-defined tumor antigens. Curr. Opin. Immunol. 9:684.
2. Rosenberg, S. A. 1997. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol. Today 18:175.
3. Feltkamp, M. C., H. L. Smits, M. P. Vierboom, R. P. Minnaar, B. M. de Jongh, J. W. Drijhout, J. ter Schegget, C. J. Melief, and W. M. Kast. 1993. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur. J. Immunol. 23:2242.
4. Marchand, M., P. Weynants, E. Rankin, F. Arienti, F. Belli, G. Parmiani, N. Cascinelli, A. Bourlond, R. Vanwijck, Y. Humblet, et al. 1995. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int. J. Cancer 63:883.
5. Parmiani, G. 1993. Tumor immunity as autoimmunity: tumor antigens include normal self proteins which stimulate anergic peripheral T cells. Immunol. Today 14:536.
6. Dubois, N., M. Bennoun, I. Allemand, T. Molina, G. Grimber, M. Daudet-Monsac, R. Abelanet, and P. Briand. 1991. Time-course development of differentiated hepatocarcinoma and lung metastasis in transgenic mice. J. Hepatol. 13:227.
7. Romieu, R., V. Lacabanne, M. Kayibanda, B. Antoine, M. Bennoun, S. Chouaib, J.-G. Guillet, and M. Viguier. 1997. Critical stages of tumor growth regulation in transgenic mice harboring a hepatocellular carcinoma revealed by distinct patterns of tumor necrosis factor-α and transforming growth factor-β mRNA production. Int. Immunol. 9:1405.
8. Milich, D. R., J. L. Hughes, A. McLachlan, G. B. Thornton, and A. Moriarty. 1988. Hepatitis B synthetic immunogen comprised of nucleocapsid T-cell sites and a envelope B-cell epitope. Proc. Natl. Acad. Sci. USA 85:1610.
9. Sette, A., A. Vitiello, B. Reherman, P. Fowler, R. Nayersina, W. M. Kast, C. J. Melief, C. Oseroff, L. Yuan, J. Ruppert, et al. 1994. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J. Immunol. 153:5586.
10. + T cells using an ELISPOT assay. J. Immunol. Methods 181:45.
11. b-restricted cytotoxic T-lymphocyte recognition epitopes in simian virus 40 T antigen. J. Virol. 66:440.
12. b-restricted determinant in simian virus 40 tumor antigen. Virology 208: 159.
13. b-restricted cytotoxic T lymphocyte epitopes within simian virus 40 T antigen. J. Virol. 69:6665.
14. Lacabanne, V., M. Viguier, R. Romieu, M. Kayibanda, F. Connan, S. Sermet, B. Antoine, J.-G. Guillet, and J. Choppin. 1998. Differential presentation of endogenously processed CTL epitopes by mouse hepatocarcinoma cell lines induced by SV40 large T antigen. Int. Immunol. 10:463.
15. Schulz, M., R. M. Zinkernagel, and H. Hengartner. 1991. Peptide-induced anti-viral protection by cytotoxic T cells. Proc. Natl. Acad. Sci. USA 88:991.
16. Kast, W. M., L. Roux, J. Curren, H. J. Blom, A. C. Voordouw, R. H. Meloen, D. Kolakofsky, and C. J. Melief. 1991. Protection against lethal Sendai virus infection by in vivo priming of virus-specific T lymphocytes with a free synthetic peptide. Proc. Natl. Acad. Sci. USA 88:2283.
17. + memory T cells. J. Exp. Med. 186:859.
18. Kurt-Jones, E. A., S. Hamberg, J. Ohara, W. E. Paul, and A. K. Abbas. 1987. Heterogeneity of helper/inducer T lymphocytes: lymphokine production and lymphokine responsiveness. J. Exp. Med. 166:1774.
19. Miller, J. F., and R. A. Flavell. 1994. T-cell tolerance and autoimmunity in transgenic models of central and peripheral tolerance. Curr. Opin. Immunol. 6:892.
20. Theobald, M., J. Biggs, J. Hernandez, J. Lustgarten, C. Labadie, and L. A. Sherman. 1997. Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. J. Exp. Med. 185:833.
21. Morgan, D. T., H. T. Keuwel, S. Fleck, H. I. Levitsky, D. M. Pardoll, and L. A. Sherman. 1998. Activation of low-avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. J. Immunol. 160:643.
22. Yee, C., S. R. Riddell, and P. D. Greenberg. 1997. Prospects for adoptive T cell therapy. Curr. Opin. Immunol. 9:702.